Santhera to present novel data highlighting the clinical relevance of peak expiratory flow as predictor of disease progression in Duchenne muscular dystrophy | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Santhera to present novel data highlighting the clinical relevance of peak expiratory flow as predictor of disease progression in Duchenne muscular dystrophy


Santhera Pharmaceuticals announces that new data further supporting the clinical relevance of Peak Expiratory Flow (PEF) and providing a link between the treatment effect of idebenone observed in the pivotal phase III DELOS study and measures of disease progression will be presented at the 15th International Congress on Neuromuscular Diseases (ICNMD) from July 6-10, 2018, in Vienna, Austria.

At Santhera’s lunchtime symposium on Sunday, July 8, a panel of clinical experts will present new data from natural history studies that support Peak Expiratory Flow as clinically relevant primary study endpoint. This new data shows that

-Peak Expiratory Flow as percent predicted (PEF%p) is a sensitive and early marker of respiratory function decline in DMD applicable over a wide age range.

https://www.duchennexchange.org/wp-content/uploads/2018/07/santhera.jpg